Clinical progression, disease severity, and mortality among adults hospitalized with COVID-19 caused by the Omicron and Delta SARS-CoV-2 variants : A population-based, matched cohort study
Copyright: © 2023 COVID-19 Omicron Delta study group. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited..
BACKGROUND: To compare the intrinsic virulence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) omicron variant with the delta variant in hospitalized adults with coronavirus disease 2019 (COVID-19).
METHODS: All adults hospitalized in the Capital Region of Copenhagen with a positive reverse transcription polymerase chain reaction test for SARS-CoV-2 and an available variant determination from 1 September 2021 to 11 February 2022. Data from health registries and patient files were used. Omicron and Delta patients were matched (1:1) by age, sex, comorbidities, and vaccination status. We calculated crude and adjusted hazard ratios (aHRs) for severe hypoxemia and mortality at 30 and 60 days.
RESULTS: 1,043 patients were included. Patients with Omicron were older, had more comorbidities, were frailer, and more often had three vaccine doses than those with Delta. Fewer patients with Omicron developed severe hypoxemia than those with Delta (aHR, 0.55; 95% confidence interval, 0.38-0.78). Omicron patients exhibited decreased aHR for 30-day mortality compared to Delta (aHR, 0.61; 0.39-0.95). Omicron patients who had received three vaccine doses had lower mortality compared to Delta patients who received three doses (aHR, 0.31;0.16-0.59), but not among those who received two or 0-1 doses (aHR, 0.86; 0.41-1.84 and 0.94; 0.49-1.81 respectively). Similar findings were observed for mortality at 60 days. Similar outcomes were obtained in the analyses of 316 individually matched patients.
CONCLUSIONS: Among adults hospitalized with COVID-19, those with Omicron had less severe hypoxemia and nearly 40% higher 30- and 60-day survival, as compared with those with Delta, mainly driven by a larger proportion of Omicron patients vaccinated with three doses of an mRNA vaccine.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
PloS one - 18(2023), 4 vom: 26., Seite e0282806 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
COVID-19 Omicron Delta study group [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 01.05.2023 Date Revised 26.10.2023 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.1371/journal.pone.0282806 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356080730 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356080730 | ||
| 003 | DE-627 | ||
| 005 | 20231226065711.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1371/journal.pone.0282806 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1186.xml |
| 035 | |a (DE-627)NLM356080730 | ||
| 035 | |a (NLM)37104488 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a COVID-19 Omicron Delta study group |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical progression, disease severity, and mortality among adults hospitalized with COVID-19 caused by the Omicron and Delta SARS-CoV-2 variants |b A population-based, matched cohort study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.05.2023 | ||
| 500 | |a Date Revised 26.10.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright: © 2023 COVID-19 Omicron Delta study group. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. | ||
| 520 | |a BACKGROUND: To compare the intrinsic virulence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) omicron variant with the delta variant in hospitalized adults with coronavirus disease 2019 (COVID-19) | ||
| 520 | |a METHODS: All adults hospitalized in the Capital Region of Copenhagen with a positive reverse transcription polymerase chain reaction test for SARS-CoV-2 and an available variant determination from 1 September 2021 to 11 February 2022. Data from health registries and patient files were used. Omicron and Delta patients were matched (1:1) by age, sex, comorbidities, and vaccination status. We calculated crude and adjusted hazard ratios (aHRs) for severe hypoxemia and mortality at 30 and 60 days | ||
| 520 | |a RESULTS: 1,043 patients were included. Patients with Omicron were older, had more comorbidities, were frailer, and more often had three vaccine doses than those with Delta. Fewer patients with Omicron developed severe hypoxemia than those with Delta (aHR, 0.55; 95% confidence interval, 0.38-0.78). Omicron patients exhibited decreased aHR for 30-day mortality compared to Delta (aHR, 0.61; 0.39-0.95). Omicron patients who had received three vaccine doses had lower mortality compared to Delta patients who received three doses (aHR, 0.31;0.16-0.59), but not among those who received two or 0-1 doses (aHR, 0.86; 0.41-1.84 and 0.94; 0.49-1.81 respectively). Similar findings were observed for mortality at 60 days. Similar outcomes were obtained in the analyses of 316 individually matched patients | ||
| 520 | |a CONCLUSIONS: Among adults hospitalized with COVID-19, those with Omicron had less severe hypoxemia and nearly 40% higher 30- and 60-day survival, as compared with those with Delta, mainly driven by a larger proportion of Omicron patients vaccinated with three doses of an mRNA vaccine | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Harboe, Zitta Barrella |e investigator |4 oth | |
| 700 | 1 | |a Roed, Casper |e investigator |4 oth | |
| 700 | 1 | |a Holler, Jon G. |e investigator |4 oth | |
| 700 | 1 | |a Khan, Fahim Iqbal |e investigator |4 oth | |
| 700 | 1 | |a Abdulrahman, Aya Nihad Abdulrahman |e investigator |4 oth | |
| 700 | 1 | |a Mülverstedt, Stefan Lundby |e investigator |4 oth | |
| 700 | 1 | |a Lindgaard-Jensen, Betina |e investigator |4 oth | |
| 700 | 1 | |a Bertelsen, Barbara Bonnesen |e investigator |4 oth | |
| 700 | 1 | |a Søborg, Christian |e investigator |4 oth | |
| 700 | 1 | |a Nielsen, Thyge Lynghøj |e investigator |4 oth | |
| 700 | 1 | |a Hansen, Line Vinum |e investigator |4 oth | |
| 700 | 1 | |a Madsen, Birgitte Lindegaard |e investigator |4 oth | |
| 700 | 1 | |a Browatzki, Andrea |e investigator |4 oth | |
| 700 | 1 | |a Eiberg, Mads |e investigator |4 oth | |
| 700 | 1 | |a Bernhard, Peter Haahr |e investigator |4 oth | |
| 700 | 1 | |a Pedersen, Emilie Marie Juelstorp |e investigator |4 oth | |
| 700 | 1 | |a Egelund, Gertrud Baunbaek |e investigator |4 oth | |
| 700 | 1 | |a Dungu, Arnold Matovu |e investigator |4 oth | |
| 700 | 1 | |a Sejdic, Adin |e investigator |4 oth | |
| 700 | 1 | |a Mathiesen, Inger Hee Mabuza |e investigator |4 oth | |
| 700 | 1 | |a Jespersen, Naja Z. |e investigator |4 oth | |
| 700 | 1 | |a Petersen, Pelle Trier |e investigator |4 oth | |
| 700 | 1 | |a Nielsen, Lars |e investigator |4 oth | |
| 700 | 1 | |a Jepsen, Micha Phill Grønholm |e investigator |4 oth | |
| 700 | 1 | |a Pedersen, Thomas Ingemann |e investigator |4 oth | |
| 700 | 1 | |a Eriksson, Robert |e investigator |4 oth | |
| 700 | 1 | |a Seitz-Rasmussen, Hans Eric Sebastian |e investigator |4 oth | |
| 700 | 1 | |a Bestle, Morten |e investigator |4 oth | |
| 700 | 1 | |a Andersen, Henrik |e investigator |4 oth | |
| 700 | 1 | |a Skram, Ulrik |e investigator |4 oth | |
| 700 | 1 | |a Skøtt, Rømer |e investigator |4 oth | |
| 700 | 1 | |a Altaraihi, Sarah |e investigator |4 oth | |
| 700 | 1 | |a Sivapalan, Pradeesh |e investigator |4 oth | |
| 700 | 1 | |a Jensen, Jens-Ulrik Stæhr |e investigator |4 oth | |
| 700 | 1 | |a Bagge, Kristian |e investigator |4 oth | |
| 700 | 1 | |a Jørgensen, Kristina Melbardis |e investigator |4 oth | |
| 700 | 1 | |a Knudsen, Maja Johanne Søndergaard |e investigator |4 oth | |
| 700 | 1 | |a Leineweber, Thomas |e investigator |4 oth | |
| 700 | 1 | |a Schneider, Uffe Vest |e investigator |4 oth | |
| 700 | 1 | |a Ahlström, Magnus Glindvad |e investigator |4 oth | |
| 700 | 1 | |a Rytter, Sofie |e investigator |4 oth | |
| 700 | 1 | |a le Dous, Nina |e investigator |4 oth | |
| 700 | 1 | |a Ravn, Pernille |e investigator |4 oth | |
| 700 | 1 | |a Reite, Nanna |e investigator |4 oth | |
| 700 | 1 | |a Podlekareva, Daria |e investigator |4 oth | |
| 700 | 1 | |a Knudsen, Andreas |e investigator |4 oth | |
| 700 | 1 | |a Johnsen, Stine |e investigator |4 oth | |
| 700 | 1 | |a Kristensen, Lars-Erik |e investigator |4 oth | |
| 700 | 1 | |a Leding, Cæcilie |e investigator |4 oth | |
| 700 | 1 | |a Hertz, Bastian Bryan |e investigator |4 oth | |
| 700 | 1 | |a Benfield, Thomas |e investigator |4 oth | |
| 700 | 1 | |a Kirk, Ole |e investigator |4 oth | |
| 700 | 1 | |a Holler, Jon Gitz |e investigator |4 oth | |
| 700 | 1 | |a Ostrowski, Sisse Rye |e investigator |4 oth | |
| 700 | 1 | |a Perner, Anders |e investigator |4 oth | |
| 700 | 1 | |a Kirkby, Nikolai |e investigator |4 oth | |
| 700 | 1 | |a Pedersen, Martin Schou |e investigator |4 oth | |
| 700 | 1 | |a van Wijhe, Maarten |e investigator |4 oth | |
| 700 | 1 | |a Simonsen, Lone |e investigator |4 oth | |
| 700 | 1 | |a Bager, Peter Michael |e investigator |4 oth | |
| 700 | 1 | |a Krause, Tyra Grove |e investigator |4 oth | |
| 700 | 1 | |a Voldstedlund, Marianne |e investigator |4 oth | |
| 700 | 1 | |a Christiansen, Lasse Engbo |e investigator |4 oth | |
| 700 | 1 | |a Stegger, Marc |e investigator |4 oth | |
| 700 | 1 | |a Cohen, Arieh |e investigator |4 oth | |
| 700 | 1 | |a Fonager, Jannik |e investigator |4 oth | |
| 700 | 1 | |a Fomsgaard, Anders |e investigator |4 oth | |
| 700 | 1 | |a Legarth, Rebecca |e investigator |4 oth | |
| 700 | 1 | |a Rasmussen, Morten |e investigator |4 oth | |
| 700 | 1 | |a Gubbels, Sophie |e investigator |4 oth | |
| 700 | 1 | |a Wohlfahrt, Jan |e investigator |4 oth | |
| 700 | 1 | |a Lillebæk, Troels |e investigator |4 oth | |
| 700 | 1 | |a Johannesen, Caroline Klint |e investigator |4 oth | |
| 700 | 1 | |a van Wijhe, Maarten |e investigator |4 oth | |
| 700 | 1 | |a Fischer, Thea K |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t PloS one |d 2006 |g 18(2023), 4 vom: 26., Seite e0282806 |w (DE-627)NLM167327399 |x 1932-6203 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2023 |g number:4 |g day:26 |g pages:e0282806 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1371/journal.pone.0282806 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2023 |e 4 |b 26 |h e0282806 | ||